# Attralus

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/attralus

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.attralus.com
- Total disclosed funding: $198M
- Latest round: Series B (Jan 26, 2024)
- Investors on record: 10

## About

Based in California, US, and founded in 2019 by co-founders Dr. Jonathan Wall and Spencer Guthrie, Attralus, Inc. formerly known as Aurora Bio, Inc., operates as a biopharmaceutical company that develops immunotherapies and an imaging diagnostic platform used for treating systemic amyloid diseases by removing existing amyloid deposits in the organs and tissues. In September, the company raised USD 116 million Series B funding led by Logos Capital, with participation from Janus Henderson Investors, Redmile Group, Samsara BioCapital, Sarissa Capital Management, Surveyor Capital, Vivo Capital, and venBio Partners. In September 2021, Attralus appoints Alexander Denner, Ph.D., and Jake Bauer to the Board of Directors

Attralus specializes in the research and development of immunotherapies such as the pan-amyloid removal (PAR) therapeutics, designed to eliminate toxic, disease-causing amyloid in organs, and tissues of patients with systemic amyloidosis. The PAR therapeutic approach targets the underlying disease in all types of systemic amyloidosis. 

Attralus plans to advance its pipeline of transformational pan-amyloid removal (PAR) therapeutics into clinical trials. The first PAR therapeutic, AT-03, is expected to begin a Phase 1 biodistribution study in patients with systemic amyloidosis. It also plans to advance the AT-01 clinical program, which uses amyloid radiotracer to detect all types of amyloid deposits in major organs such as the heart, kidney, liver, and spleen. The September 2021 Series B funding will also help expand Attralus' team and infrastructure to support its future growth.

## Funding rounds

- Series B, Jan 26, 2024, $56M — Vivo Capital, VenBio, Sarissa Capital Management, Bristol-Myers Squibb, Surveyor Capital, Logos Capital, Alpha Wave Global LP
- Series B, Aug 31, 2021, $117M — Vivo Capital, Redmile Group, VenBio, Sarissa Capital Management, Janus Henderson Investors, Samsara BioCapital, Surveyor Capital, Logos Capital
- Series A, Sep 14, 2020, $26M — VenBio

## Investors

- VenBio (https://capitalatlas.ai/funds/venbio) — Series A, Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B
- Sarissa Capital Management — Series B
- Janus Henderson Investors — Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B
- Surveyor Capital — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B
- Bristol-Myers Squibb — Series B
- Alpha Wave Global LP — Series B